Clinical Study Data Request Registered Users, Please Login

Proposal 1073

Title of the Proposed Research

End-of-life trajectories in COPD

Lead Researcher

Dr. Daisy J.A. Janssen


CIRO, Centre of Expertise for Chronic Organ Failure
Maastricht University Medical Centre (MUMC)
Maastricht, The Netherlands

Funding Source


Potential Conflicts of Interest


Data Sharing Agreement Date

16 October 2014

Lay Summary

Chronic Obstructive Pulmonary Disease (COPD) affects millions of people worldwide and is a major cause of death. Previously, a hypothetical end-of-life trajectory was described for patients with COPD: a gradual decline in health status, punctuated by acute deteriorations with partial recovery. Whether most people with end stage COPD follow this trajectory or other disease trajectories remains unknown. Insight in the disease trajectories in COPD is important to inform healthcare services and to communicate prognosis and the expected end-of-life trajectory with patients and their loved ones. Therefore, the aim of the current proposal is to explore whether and to what extent individual end-of-life trajectories conform the hypothetical end-of-life trajectory in COPD. More specific, objectives are: 1) to study the course of disease-specific health status at the end-of-life among patients with COPD; 2) to study the occurrence of exacerbations and COPD-related hospital admissions at the end-of-life; and 3) to identify different end-of-life trajectories in COPD. For this study we aim to analyse data from patients with COPD who previously participated in the study “Towards a Revolution in COPD Health” (TORCH) and died within three years follow-up. We will prepare a publication from this analysis for an international scientific journal. In addition we will provide a lay summary.

Study Data Provided

Study SCO30003: A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (SERETIDE® inhaler) 50/500mcg BD, salmeterol 50mcg BD and fluticasone propionate 500mcg BD, all delivered via the DISKUS®/ACCUHALER® inhaler, on mortality and morbidity of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment

Statistical Analysis Plan

This will be added after the research is published.

Publication Citation